ABSTRACT:
50 samples from patients with inflammatory bowel disease who visited Marjan Hospital and Al-Hilla Teaching Hospital for both sexes were collected for the stream study. Ages 20 to 70 were represented by 30 samples of women and 20 samples of males. According to the findings, there were 60% more women than men. The level of hsp32 was tested since it was discovered that levels of the protein rose with age (61-70 years), reaching a level of 262.0000013.11488pg/ml as opposed to the level in the control group (158.3333118.24692pg/ml). The amount of hsp60 was examined, and it was discovered that it rose with age (61-70years), reaching a concentration of (90.0000 3.00000pg/ml) compared to control (80.0000 2.00000pg/ml).
Cite this article:
Zainab. Nasser. Nabat, Ali d.marhash, Bareq A. Al-lateef. Detection of Heat Shock Protein 32 and Heat Shock protein 60 in patients with Inflammatory Bowel Disease. Research Journal of Pharmacy and Technology 2023; 16(9):4135-7. doi: 10.52711/0974-360X.2023.00676
Cite(Electronic):
Zainab. Nasser. Nabat, Ali d.marhash, Bareq A. Al-lateef. Detection of Heat Shock Protein 32 and Heat Shock protein 60 in patients with Inflammatory Bowel Disease. Research Journal of Pharmacy and Technology 2023; 16(9):4135-7. doi: 10.52711/0974-360X.2023.00676 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2023-16-9-20
REFERENCES:
1. Prerna Dubey, Sumithra. M, Chitra. V. Assessment of Inflammatory Bowel Disease and its Herbal Cure: A Review. Research J. Pharm. and Tech. 2019; 12(3): 1432-1440. doi: 10.5958/0974-360X.2019.00238.5
2. Prajapati KV, Jain VC, Prajapati N. Pharmacology of combined Mesalazine and Rifaximin Therapy to Inflammatory Bowel Disease. Asian J Pharm Tech. 2016; 6(1): 45-50.
3. Dhole AR, Shendage GG, Pethkar S, Magdum CS, Mohite SK. Drug used in Inflammatory Bowel Disease (IBD)-Brief Review. Research J Pharmacology Pharmacodynamics. 2014; 6(3): 153-161.
4. S.G.R.G. Barton, D.S. Rampton, V.R. Winrow, P. Domizio, and R.M. Feakins. Expression of heat shock protein 32 (hemoxygenase-1) in the normal andinflamed human stomach and colon:an immunohistochemical study. Cell Stress and Chaperones. 2003; 8(4): 329–334
5. Susmi M S, Revathy S Kumar, Sreelakshmi V, Sruthy V Menon, Surya Mohan, SaranyaTulasidharanSuja, Sathianarayanan, Asha AsokanManakadan. A Computational approach for identification of Phytochemicals for targeting and optimizing the inhibitors of Heat shock proteins. Research J. Pharm. and Tech. 2015; 8(9): 1199-1204. doi: 10.5958/0974-360X.2015.00219.X.
6. K. N. Anitha, K. M. Geetha. Soluble Epoxide Hydrolase: A Pharmaceutical Target for Inflammation. Research J. Pharm. and Tech. 2019; 12(10):5113-5118. doi: 10.5958/0974-360X.2019.00886.2.
7. C. Barbatis, M. Tsopanomichalou. Heat Shock Proteins in InflammatoryBowel Disease. J. Annals of Gastroenterology. 2009; 22(4): 244-247
8. Rohitas Deshmukh. Development and In‑Vitro Evaluation of Colon Specific Indomethacin Matrix Tablet for the Treatment of Inflammatory Bowel Disease. Research Journal of Pharmacy and Technology. 2021; 14(5):2391-6. doi: 10.52711/0974-360X.2021.00422
9. Cappello, F.; Mazzola, M.; Jurjus, A.; Zeenny, M.-N.; Jurjus, R.; Carini, F.; Leone, A.; Bonaventura, G.;Tomasello, G.; Bucchieri, F.; et al. Hsp60 as a Novel Target in IBD Management: A Prospect. Front. Pharmacol. 2019, 10, 26.
10. Sangiorgi, C.; Vallese, D.; Gnemmi, I.; Bucchieri, F.; Balbi, B.; Brun, P.; Leone, A.; Giordano, A.; Conway deMacario, E.; Macario, A.J.L.; et al. HSP60 activity on human bronchial epithelial cells. Int. J. Immunopathol. Pharmacol. 2017, 30, 333–340.
11. Rodolico, V.; Tomasello, G.; Zerilli, M.; Martorana, A.; Pitruzzella, A.; Gammazza, A.M.; David, S.; Zummo, G.;Damiani, P.; Accomando, S.; et al. Hsp 60 and Hsp10 increase in colon mucosa of Crohn’s disease andulcerative colitis. Cell Stress Chaperones. 2010; 15: 877–884.
12. Rohitas Deshmukh, SujataKumari, Ranjit K. Harwansh. Inflammatory Bowel Disease: A Snapshot of Current Knowledge. Research J. Pharm. and Tech. 2020; 13(2):956-962. doi: 10.5958/0974-360X.2020.00180.8.
13. Rajalekshmi M, Shreedhara CS, Lobo R, Rao PP. The review on genetics, epigenetics, risk factors and diagnosis of colon cancer. Research Journal of Pharmacy and Technology. 2018; 11(11); 5147-5151.
14. Vivan TK, Santos CHM, Santos BM. Quality of life of patients withinflammatory bowel disease. J Coloproctol. 2017; 37(4): 279-84. doi:10.1016/j.jcol.2017.06.009.
15. Thomas Greutera Christine Manserb Valerie Pittetc Stephan R. VavrickaLuc Biedermanna on behalf of Swiss IBDnet, an official working group of theSwiss Society of Gastroenterology,Gender Differences in Inflammatory Bowel Disease. J. Digestion. 2020; 101(suppl 1):98–104.
16. Shah SC, Khalili H, Gower-Rousseau C, Olen O, Benchimol EI, Lynge E, et al. Sex-Based Differences in Incidence of Inflammatory Bowel Diseases-Pooled Analysis of Population-Based Studies From Western Countries. Gastroenterology. 2018; 155(4): 1079–1089.
17. Vavricka SR, Spigaglia SM, Rogler G, PittetV,Michetti P, Felley C, et al.; Swiss IBD Cohort Study Group. Systematic evaluation of risk factors for diagnostic delay in inflammatorybowel disease. Inflamm Bowel Dis. 2012; 18(3): 496–505.
18. Malago JJ, K oninkx JF, van Dijk JE. The heat shock responseandcytoprotection of the intestinal epithelium. Cell StressChaperones. 2002; 7:191-199.
19. Klausz G, Molnár T, Nagy F, Gyulai Z, Boda K , LonovicsJ, Mándi Y. Polymorphism of the heat-shock protein geneHsp70-2, but not polymorphisms of the IL-10 and CD14 genes, is associated with the outcome of Crohn’s disease.Scand J Gastroenterol. 2005; 40:1197-204.